Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Affiliations

• ¹ Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
• ² Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.
• ³ University Hospital of Salamanca, Salamanca, Spain.
• ⁴ Moffitt Cancer Center, Tampa, FL, USA.
• ⁵ Hôpital Saint-Louis, Université de Paris 7, Paris, France.
• ⁶ Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
• ⁷ Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
• ⁸ Hospital Universitario Vall d'Hebron, Barcelona, Spain.
• ⁹ Grande Ospedale Metropolitano BMM, Reggio Calabria, Italy.
• ¹⁰ Modus Outcomes, A Division of THREAD, Lyon, France.
• ¹¹ Geron Corporation, Parsippany, NJ, USA.
• ¹² Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA.
• ¹³ Leipzig University Hospital, Leipzig, Germany.